Kavita ici final master 1226
2025-12-26
read master
1year
| Characteristic | N = 10,0371 |
|---|---|
| Age | 69 (60, 76) |
| Gender_Legal_Sex | |
| Female | 4,805 (48%) |
| Male | 5,232 (52%) |
| male | |
| 0 | 4,805 (48%) |
| 1 | 5,232 (52%) |
| Race | |
| Asian | 297 (3.0%) |
| Black | 284 (2.8%) |
| Other/Unknown | 422 (4.2%) |
| White | 9,034 (90%) |
| Ethnic_Group | |
| Hispanic | 9,428 (94%) |
| Non_hispanic | 609 (6.1%) |
| ckd_incidence_1year | |
| 0 | 9,778 (97%) |
| 1 | 259 (2.6%) |
| ckd_progression_1year | |
| 0 | 8,935 (89%) |
| 1 | 1,102 (11%) |
| eskd_composite_1year | |
| 0 | 10,006 (100%) |
| 1 | 31 (0.3%) |
| ckd_composite_1year | |
| 0 | 8,664 (86%) |
| 1 | 1,373 (14%) |
| ckd_stage_1year | |
| 1 | 4,156 (41%) |
| 2 | 4,116 (41%) |
| 3 | 1,647 (16%) |
| 4 | 105 (1.0%) |
| 5 | 13 (0.1%) |
| ckd_stage_baseline | |
| 1 | 4,635 (46%) |
| 2 | 4,034 (40%) |
| 3 | 1,289 (13%) |
| 4 | 75 (0.7%) |
| 5 | 4 (<0.1%) |
| dm | |
| 0 | 8,669 (86%) |
| 1 | 1,368 (14%) |
| htn | |
| 0 | 4,132 (41%) |
| 1 | 5,905 (59%) |
| cad | |
| 0 | 7,947 (79%) |
| 1 | 2,090 (21%) |
| ace_arb | |
| 0 | 5,590 (56%) |
| 1 | 4,447 (44%) |
| diu | |
| 0 | 4,752 (47%) |
| 1 | 5,285 (53%) |
| ppi | |
| 0 | 2,823 (28%) |
| 1 | 7,214 (72%) |
| steroids | |
| 0 | 2,718 (27%) |
| 1 | 7,319 (73%) |
| smoking | |
| 0 | 4,942 (49%) |
| 1 | 5,095 (51%) |
| Bevacizumab | |
| 0 | 9,368 (93%) |
| 1 | 669 (6.7%) |
| Cisplatin | |
| 0 | 8,728 (87%) |
| 1 | 1,309 (13%) |
| Carboplatin | |
| 0 | 6,947 (69%) |
| 1 | 3,090 (31%) |
| Pemetrexed | |
| 0 | 8,715 (87%) |
| 1 | 1,322 (13%) |
| Gemcitabine | |
| 0 | 8,832 (88%) |
| 1 | 1,205 (12%) |
| Cetuximab | |
| 0 | 9,808 (98%) |
| 1 | 229 (2.3%) |
| Trastuzumab | |
| 0 | 9,745 (97%) |
| 1 | 292 (2.9%) |
| VEGF_TKI | |
| 0 | 9,200 (92%) |
| 1 | 837 (8.3%) |
| pre_CRE_180days | 0.86 (0.72, 1.04) |
| pre_HGB_180days | 12.70 (11.40, 13.80) |
| Unknown | 10 |
| pre_ALB_180days | 4.10 (3.90, 4.40) |
| Unknown | 39 |
| eGFR_CRE_baseline | 88 (71, 99) |
| 1 Median (Q1, Q3); n (%) | |
2year
| Characteristic | N = 6,3001 |
|---|---|
| Age | 69 (60, 77) |
| Gender_Legal_Sex | |
| Female | 2,959 (47%) |
| Male | 3,341 (53%) |
| male | |
| 0 | 2,959 (47%) |
| 1 | 3,341 (53%) |
| Race | |
| Asian | 168 (2.7%) |
| Black | 158 (2.5%) |
| Other/Unknown | 249 (4.0%) |
| White | 5,725 (91%) |
| Ethnic_Group | |
| Hispanic | 5,911 (94%) |
| Non_hispanic | 389 (6.2%) |
| ckd_incidence_2year | |
| 0 | 5,966 (95%) |
| 1 | 334 (5.3%) |
| ckd_progression_2year | |
| 0 | 5,559 (88%) |
| 1 | 741 (12%) |
| eskd_composite_2year | |
| 0 | 6,274 (100%) |
| 1 | 26 (0.4%) |
| ckd_composite_2year | |
| 0 | 5,216 (83%) |
| 1 | 1,084 (17%) |
| ckd_stage_1year | |
| 1 | 2,454 (39%) |
| 2 | 2,738 (43%) |
| 3 | 1,050 (17%) |
| 4 | 54 (0.9%) |
| 5 | 4 (<0.1%) |
| ckd_stage_2year | |
| 1 | 2,356 (37%) |
| 2 | 2,779 (44%) |
| 3 | 1,090 (17%) |
| 4 | 67 (1.1%) |
| 5 | 8 (0.1%) |
| ckd_stage_baseline | |
| 1 | 2,870 (46%) |
| 2 | 2,600 (41%) |
| 3 | 784 (12%) |
| 4 | 43 (0.7%) |
| 5 | 3 (<0.1%) |
| dm | |
| 0 | 5,481 (87%) |
| 1 | 819 (13%) |
| htn | |
| 0 | 2,621 (42%) |
| 1 | 3,679 (58%) |
| cad | |
| 0 | 5,025 (80%) |
| 1 | 1,275 (20%) |
| ace_arb | |
| 0 | 3,423 (54%) |
| 1 | 2,877 (46%) |
| diu | |
| 0 | 3,033 (48%) |
| 1 | 3,267 (52%) |
| ppi | |
| 0 | 1,764 (28%) |
| 1 | 4,536 (72%) |
| steroids | |
| 0 | 1,743 (28%) |
| 1 | 4,557 (72%) |
| smoking | |
| 0 | 3,083 (49%) |
| 1 | 3,217 (51%) |
| Bevacizumab | |
| 0 | 5,938 (94%) |
| 1 | 362 (5.7%) |
| Cisplatin | |
| 0 | 5,511 (87%) |
| 1 | 789 (13%) |
| Carboplatin | |
| 0 | 4,545 (72%) |
| 1 | 1,755 (28%) |
| Pemetrexed | |
| 0 | 5,504 (87%) |
| 1 | 796 (13%) |
| Gemcitabine | |
| 0 | 5,607 (89%) |
| 1 | 693 (11%) |
| Cetuximab | |
| 0 | 6,178 (98%) |
| 1 | 122 (1.9%) |
| Trastuzumab | |
| 0 | 6,123 (97%) |
| 1 | 177 (2.8%) |
| VEGF_TKI | |
| 0 | 5,742 (91%) |
| 1 | 558 (8.9%) |
| pre_CRE_180days | 0.86 (0.72, 1.04) |
| pre_HGB_180days | 12.80 (11.60, 14.00) |
| Unknown | 6 |
| pre_ALB_180days | 4.20 (3.90, 4.40) |
| Unknown | 26 |
| eGFR_CRE_baseline | 88 (72, 99) |
| 1 Median (Q1, Q3); n (%) | |
3year
| Characteristic | N = 3,9411 |
|---|---|
| Age | 70 (61, 77) |
| Gender_Legal_Sex | |
| Female | 1,812 (46%) |
| Male | 2,129 (54%) |
| male | |
| 0 | 1,812 (46%) |
| 1 | 2,129 (54%) |
| Race | |
| Asian | 87 (2.2%) |
| Black | 87 (2.2%) |
| Other/Unknown | 150 (3.8%) |
| White | 3,617 (92%) |
| Ethnic_Group | |
| Hispanic | 3,696 (94%) |
| Non_hispanic | 245 (6.2%) |
| ckd_incidence_3year | |
| 0 | 3,659 (93%) |
| 1 | 282 (7.2%) |
| ckd_progression_3year | |
| 0 | 3,493 (89%) |
| 1 | 448 (11%) |
| eskd_composite_3year | |
| 0 | 3,922 (100%) |
| 1 | 19 (0.5%) |
| ckd_composite_3year | |
| 0 | 3,203 (81%) |
| 1 | 738 (19%) |
| ckd_stage_1year | |
| 1 | 1,530 (39%) |
| 2 | 1,745 (44%) |
| 3 | 635 (16%) |
| 4 | 28 (0.7%) |
| 5 | 3 (<0.1%) |
| ckd_stage_2year | |
| 1 | 1,453 (37%) |
| 2 | 1,804 (46%) |
| 3 | 652 (17%) |
| 4 | 30 (0.8%) |
| 5 | 2 (<0.1%) |
| ckd_stage_3year | |
| 1 | 1,399 (35%) |
| 2 | 1,831 (46%) |
| 3 | 654 (17%) |
| 4 | 49 (1.2%) |
| 5 | 8 (0.2%) |
| ckd_stage_baseline | |
| 1 | 1,810 (46%) |
| 2 | 1,633 (41%) |
| 3 | 476 (12%) |
| 4 | 20 (0.5%) |
| 5 | 2 (<0.1%) |
| dm | |
| 0 | 3,464 (88%) |
| 1 | 477 (12%) |
| htn | |
| 0 | 1,622 (41%) |
| 1 | 2,319 (59%) |
| cad | |
| 0 | 3,178 (81%) |
| 1 | 763 (19%) |
| ace_arb | |
| 0 | 2,104 (53%) |
| 1 | 1,837 (47%) |
| diu | |
| 0 | 1,872 (48%) |
| 1 | 2,069 (52%) |
| ppi | |
| 0 | 1,077 (27%) |
| 1 | 2,864 (73%) |
| steroids | |
| 0 | 1,087 (28%) |
| 1 | 2,854 (72%) |
| smoking | |
| 0 | 1,901 (48%) |
| 1 | 2,040 (52%) |
| Bevacizumab | |
| 0 | 3,739 (95%) |
| 1 | 202 (5.1%) |
| Cisplatin | |
| 0 | 3,489 (89%) |
| 1 | 452 (11%) |
| Carboplatin | |
| 0 | 2,955 (75%) |
| 1 | 986 (25%) |
| Pemetrexed | |
| 0 | 3,452 (88%) |
| 1 | 489 (12%) |
| Gemcitabine | |
| 0 | 3,568 (91%) |
| 1 | 373 (9.5%) |
| Cetuximab | |
| 0 | 3,876 (98%) |
| 1 | 65 (1.6%) |
| Trastuzumab | |
| 0 | 3,852 (98%) |
| 1 | 89 (2.3%) |
| VEGF_TKI | |
| 0 | 3,606 (91%) |
| 1 | 335 (8.5%) |
| pre_CRE_180days | 0.87 (0.73, 1.04) |
| pre_HGB_180days | 13.00 (11.70, 14.10) |
| Unknown | 5 |
| pre_ALB_180days | 4.20 (3.90, 4.40) |
| Unknown | 15 |
| eGFR_CRE_baseline | 88 (72, 99) |
| 1 Median (Q1, Q3); n (%) | |
4year
| Characteristic | N = 2,6161 |
|---|---|
| Age | 70 (61, 77) |
| Gender_Legal_Sex | |
| Female | 1,198 (46%) |
| Male | 1,418 (54%) |
| male | |
| 0 | 1,198 (46%) |
| 1 | 1,418 (54%) |
| Race | |
| Asian | 53 (2.0%) |
| Black | 46 (1.8%) |
| Other/Unknown | 95 (3.6%) |
| White | 2,422 (93%) |
| Ethnic_Group | |
| Hispanic | 2,443 (93%) |
| Non_hispanic | 173 (6.6%) |
| ckd_incidence_4year | |
| 0 | 2,394 (92%) |
| 1 | 222 (8.5%) |
| ckd_progression_4year | |
| 0 | 2,328 (89%) |
| 1 | 288 (11%) |
| eskd_composite_4year | |
| 0 | 2,603 (100%) |
| 1 | 13 (0.5%) |
| ckd_composite_4year | |
| 0 | 2,099 (80%) |
| 1 | 517 (20%) |
| ckd_stage_1year | |
| 1 | 1,014 (39%) |
| 2 | 1,186 (45%) |
| 3 | 395 (15%) |
| 4 | 19 (0.7%) |
| 5 | 2 (<0.1%) |
| ckd_stage_2year | |
| 1 | 972 (37%) |
| 2 | 1,217 (47%) |
| 3 | 408 (16%) |
| 4 | 18 (0.7%) |
| 5 | 1 (<0.1%) |
| ckd_stage_3year | |
| 1 | 910 (35%) |
| 2 | 1,264 (48%) |
| 3 | 417 (16%) |
| 4 | 22 (0.8%) |
| 5 | 3 (0.1%) |
| ckd_stage_4year | |
| 1 | 949 (36%) |
| 2 | 1,190 (45%) |
| 3 | 448 (17%) |
| 4 | 27 (1.0%) |
| 5 | 2 (<0.1%) |
| ckd_stage_baseline | |
| 1 | 1,226 (47%) |
| 2 | 1,071 (41%) |
| 3 | 308 (12%) |
| 4 | 10 (0.4%) |
| 5 | 1 (<0.1%) |
| dm | |
| 0 | 2,313 (88%) |
| 1 | 303 (12%) |
| htn | |
| 0 | 1,067 (41%) |
| 1 | 1,549 (59%) |
| cad | |
| 0 | 2,107 (81%) |
| 1 | 509 (19%) |
| ace_arb | |
| 0 | 1,378 (53%) |
| 1 | 1,238 (47%) |
| diu | |
| 0 | 1,251 (48%) |
| 1 | 1,365 (52%) |
| ppi | |
| 0 | 669 (26%) |
| 1 | 1,947 (74%) |
| steroids | |
| 0 | 742 (28%) |
| 1 | 1,874 (72%) |
| smoking | |
| 0 | 1,260 (48%) |
| 1 | 1,356 (52%) |
| Bevacizumab | |
| 0 | 2,491 (95%) |
| 1 | 125 (4.8%) |
| Cisplatin | |
| 0 | 2,334 (89%) |
| 1 | 282 (11%) |
| Carboplatin | |
| 0 | 2,032 (78%) |
| 1 | 584 (22%) |
| Pemetrexed | |
| 0 | 2,322 (89%) |
| 1 | 294 (11%) |
| Gemcitabine | |
| 0 | 2,392 (91%) |
| 1 | 224 (8.6%) |
| Cetuximab | |
| 0 | 2,580 (99%) |
| 1 | 36 (1.4%) |
| Trastuzumab | |
| 0 | 2,559 (98%) |
| 1 | 57 (2.2%) |
| VEGF_TKI | |
| 0 | 2,412 (92%) |
| 1 | 204 (7.8%) |
| pre_CRE_180days | 0.87 (0.73, 1.04) |
| pre_HGB_180days | 13.10 (11.80, 14.10) |
| Unknown | 1 |
| pre_ALB_180days | 4.20 (3.90, 4.40) |
| Unknown | 8 |
| eGFR_CRE_baseline | 88 (73, 100) |
| 1 Median (Q1, Q3); n (%) | |
5year
| Characteristic | N = 1,7781 |
|---|---|
| Age | 70 (61, 77) |
| Gender_Legal_Sex | |
| Female | 814 (46%) |
| Male | 964 (54%) |
| male | |
| 0 | 814 (46%) |
| 1 | 964 (54%) |
| Race | |
| Asian | 38 (2.1%) |
| Black | 26 (1.5%) |
| Other/Unknown | 60 (3.4%) |
| White | 1,654 (93%) |
| Ethnic_Group | |
| Hispanic | 1,655 (93%) |
| Non_hispanic | 123 (6.9%) |
| ckd_incidence_5year | |
| 0 | 1,603 (90%) |
| 1 | 175 (9.8%) |
| ckd_progression_5year | |
| 0 | 1,595 (90%) |
| 1 | 183 (10%) |
| eskd_composite_5year | |
| 0 | 1,764 (99%) |
| 1 | 14 (0.8%) |
| ckd_composite_5year | |
| 0 | 1,413 (79%) |
| 1 | 365 (21%) |
| ckd_stage_1year | |
| 1 | 707 (40%) |
| 2 | 799 (45%) |
| 3 | 261 (15%) |
| 4 | 9 (0.5%) |
| 5 | 2 (0.1%) |
| ckd_stage_2year | |
| 1 | 657 (37%) |
| 2 | 842 (47%) |
| 3 | 268 (15%) |
| 4 | 10 (0.6%) |
| 5 | 1 (<0.1%) |
| ckd_stage_3year | |
| 1 | 612 (34%) |
| 2 | 877 (49%) |
| 3 | 277 (16%) |
| 4 | 9 (0.5%) |
| 5 | 3 (0.2%) |
| ckd_stage_4year | |
| 1 | 638 (36%) |
| 2 | 833 (47%) |
| 3 | 289 (16%) |
| 4 | 16 (0.9%) |
| 5 | 2 (0.1%) |
| ckd_stage_5year | |
| 1 | 655 (37%) |
| 2 | 810 (46%) |
| 3 | 289 (16%) |
| 4 | 21 (1.2%) |
| 5 | 3 (0.2%) |
| ckd_stage_baseline | |
| 1 | 855 (48%) |
| 2 | 723 (41%) |
| 3 | 193 (11%) |
| 4 | 7 (0.4%) |
| 5 | 0 (0%) |
| dm | |
| 0 | 1,591 (89%) |
| 1 | 187 (11%) |
| htn | |
| 0 | 723 (41%) |
| 1 | 1,055 (59%) |
| cad | |
| 0 | 1,451 (82%) |
| 1 | 327 (18%) |
| ace_arb | |
| 0 | 947 (53%) |
| 1 | 831 (47%) |
| diu | |
| 0 | 844 (47%) |
| 1 | 934 (53%) |
| ppi | |
| 0 | 442 (25%) |
| 1 | 1,336 (75%) |
| steroids | |
| 0 | 513 (29%) |
| 1 | 1,265 (71%) |
| smoking | |
| 0 | 860 (48%) |
| 1 | 918 (52%) |
| Bevacizumab | |
| 0 | 1,700 (96%) |
| 1 | 78 (4.4%) |
| Cisplatin | |
| 0 | 1,590 (89%) |
| 1 | 188 (11%) |
| Carboplatin | |
| 0 | 1,405 (79%) |
| 1 | 373 (21%) |
| Pemetrexed | |
| 0 | 1,603 (90%) |
| 1 | 175 (9.8%) |
| Gemcitabine | |
| 0 | 1,631 (92%) |
| 1 | 147 (8.3%) |
| Cetuximab | |
| 0 | 1,755 (99%) |
| 1 | 23 (1.3%) |
| Trastuzumab | |
| 0 | 1,741 (98%) |
| 1 | 37 (2.1%) |
| VEGF_TKI | |
| 0 | 1,662 (93%) |
| 1 | 116 (6.5%) |
| pre_CRE_180days | 0.86 (0.72, 1.03) |
| pre_HGB_180days | 13.20 (11.90, 14.20) |
| Unknown | 1 |
| pre_ALB_180days | 4.20 (3.90, 4.40) |
| Unknown | 7 |
| eGFR_CRE_baseline | 89 (74, 100) |
| 1 Median (Q1, Q3); n (%) | |
landmark 1year
landmark 2year
landmark 3year
landmark 4year
landmark 5year
ckd_stage vs ckd_composite_5year
| 0 (N=1413) |
1 (N=365) |
Overall (N=1778) |
|
|---|---|---|---|
| ckd_stage_baseline_3 | |||
| stage 1 | 795 (56.3%) | 60 (16.4%) | 855 (48.1%) |
| stage 2 | 582 (41.2%) | 141 (38.6%) | 723 (40.7%) |
| stage 3 or more | 36 (2.5%) | 164 (44.9%) | 200 (11.2%) |
| ckd_stage_5year_3 | |||
| stage 1 | 645 (45.6%) | 10 (2.7%) | 655 (36.8%) |
| stage 2 | 697 (49.3%) | 113 (31.0%) | 810 (45.6%) |
| Missing | 71 (5.0%) | 242 (66.3%) | 313 (17.6%) |
logistic regression outcome: ckd_composite_5year
| Characteristic | N | OR1 | 95% CI1 | p-value |
|---|---|---|---|---|
| Age | 1,778 | 1.07 | 1.06, 1.09 | <0.001 |
| Gender_Legal_Sex | 1,778 | |||
| Female | — | — | ||
| Male | 1.00 | 0.80, 1.26 | 0.990 | |
| male | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.00 | 0.80, 1.26 | 0.990 | |
| Race | 1,778 | |||
| Asian | — | — | ||
| Black | 3.91 | 1.25, 13.3 | 0.022 | |
| Other/Unknown | 1.07 | 0.36, 3.40 | 0.909 | |
| White | 1.37 | 0.61, 3.66 | 0.483 | |
| Ethnic_Group | 1,778 | |||
| Hispanic | — | — | ||
| Non_hispanic | 0.88 | 0.54, 1.39 | 0.603 | |
| dm | 1,778 | |||
| 0 | — | — | ||
| 1 | 2.17 | 1.55, 3.00 | <0.001 | |
| htn | 1,778 | |||
| 0 | — | — | ||
| 1 | 2.31 | 1.79, 3.00 | <0.001 | |
| cad | 1,778 | |||
| 0 | — | — | ||
| 1 | 2.01 | 1.53, 2.63 | <0.001 | |
| ace_arb | 1,778 | |||
| 0 | — | — | ||
| 1 | 2.93 | 2.30, 3.74 | <0.001 | |
| diu | 1,778 | |||
| 0 | — | — | ||
| 1 | 3.32 | 2.57, 4.31 | <0.001 | |
| ppi | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.61 | 1.21, 2.16 | 0.001 | |
| steroids | 1,778 | |||
| 0 | — | — | ||
| 1 | 0.79 | 0.62, 1.01 | 0.057 | |
| smoking | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.39 | 1.10, 1.75 | 0.006 | |
| ckd_stage_baseline_3 | 1,778 | |||
| stage 1 | — | — | ||
| stage 2 | 3.21 | 2.34, 4.45 | <0.001 | |
| stage 3 or more | 60.4 | 39.1, 95.6 | <0.001 | |
| ckd_stage_5year_3 | 1,465 | |||
| stage 1 | — | — | ||
| stage 2 | 10.5 | 5.71, 21.5 | <0.001 | |
| Bevacizumab | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.26 | 0.72, 2.10 | 0.393 | |
| Cisplatin | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.13 | 0.78, 1.61 | 0.516 | |
| Carboplatin | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.01 | 0.76, 1.33 | 0.951 | |
| Pemetrexed | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.44 | 1.0, 2.04 | 0.048 | |
| Gemcitabine | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.81 | 1.24, 2.60 | 0.002 | |
| Cetuximab | 1,778 | |||
| 0 | — | — | ||
| 1 | 0.58 | 0.14, 1.69 | 0.377 | |
| Trastuzumab | 1,778 | |||
| 0 | — | — | ||
| 1 | 0.60 | 0.20, 1.42 | 0.291 | |
| VEGF_TKI | 1,778 | |||
| 0 | — | — | ||
| 1 | 3.37 | 2.28, 4.95 | <0.001 | |
| pre_CRE_180days | 1,778 | 59.5 | 35.8, 101 | <0.001 |
| 1 OR = Odds Ratio, CI = Confidence Interval | ||||
cox model outcome: death
| Characteristic | N | HR1 | 95% CI1 | p-value |
|---|---|---|---|---|
| Age | 1,778 | 1.00 | 1.00, 1.00 | 0.618 |
| Gender_Legal_Sex | 1,778 | |||
| Female | — | — | ||
| Male | 0.96 | 0.88, 1.06 | 0.447 | |
| male | 1,778 | |||
| 0 | — | — | ||
| 1 | 0.96 | 0.88, 1.06 | 0.447 | |
| Race | 1,778 | |||
| Asian | — | — | ||
| Black | 0.65 | 0.39, 1.07 | 0.088 | |
| Other/Unknown | 0.79 | 0.53, 1.19 | 0.265 | |
| White | 0.71 | 0.52, 0.99 | 0.041 | |
| Ethnic_Group | 1,778 | |||
| Hispanic | — | — | ||
| Non_hispanic | 0.85 | 0.71, 1.03 | 0.093 | |
| dm | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.00 | 0.86, 1.17 | 0.987 | |
| htn | 1,778 | |||
| 0 | — | — | ||
| 1 | 0.92 | 0.84, 1.02 | 0.101 | |
| cad | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.20 | 1.06, 1.35 | 0.004 | |
| ace_arb | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.01 | 0.92, 1.11 | 0.798 | |
| diu | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.03 | 0.94, 1.13 | 0.531 | |
| ppi | 1,778 | |||
| 0 | — | — | ||
| 1 | 0.86 | 0.77, 0.96 | 0.007 | |
| steroids | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.22 | 1.10, 1.35 | <0.001 | |
| smoking | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.05 | 0.96, 1.15 | 0.296 | |
| ckd_stage_baseline_3 | 1,778 | |||
| stage 1 | — | — | ||
| stage 2 | 1.08 | 0.98, 1.20 | 0.115 | |
| stage 3 or more | 1.11 | 0.95, 1.29 | 0.189 | |
| ckd_stage_5year_3 | 1,465 | |||
| stage 1 | — | — | ||
| stage 2 | 1.07 | 0.96, 1.18 | 0.224 | |
| Bevacizumab | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.08 | 0.86, 1.35 | 0.522 | |
| Cisplatin | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.34 | 1.15, 1.56 | <0.001 | |
| Carboplatin | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.36 | 1.21, 1.53 | <0.001 | |
| Pemetrexed | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.23 | 1.05, 1.43 | 0.011 | |
| Gemcitabine | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.45 | 1.22, 1.71 | <0.001 | |
| Cetuximab | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.51 | 1.00, 2.27 | 0.051 | |
| Trastuzumab | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.08 | 0.78, 1.50 | 0.627 | |
| VEGF_TKI | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.21 | 1.00, 1.46 | 0.046 | |
| pre_CRE_180days | 1,778 | 1.04 | 0.87, 1.23 | 0.697 |
| ckd_composite_5year | 1,778 | |||
| 0 | — | — | ||
| 1 | 1.12 | 1.00, 1.25 | 0.059 | |
| 1 HR = Hazard Ratio, CI = Confidence Interval | ||||